MOELLER CARSTEN
No ORCID on file
· 32 papers in corpus
other
2012
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and/or…
2011
The invention relates to 17-hydroxy-13-methyl-17-pentafluorethyl-11-acyloxyalkylenephenyl-dodecahydro-cyclopenta[a]phenanthrene-3-on derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production t…
2011
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and/or…
2011
The invention relates to 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof for the treatment and/or…
2011
The invention relates to a 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11methylene oxyalkylene aryl derivative of formula (I) exhibiting progesterone-antagonistic effects and to methods for the production thereof, to the use thereof fo…
2011
The invention relates to selective estrogen receptor modulators (SERMs) and to processes for production thereof, to the use thereof for treatment and/or prophylaxis of disorders, and to the use thereof for production of medicaments for trea…
other
2011
The present invention provides the use of mineralocorticoid receptor antagonists for preparing a medicament for the treatment of endometriosis. The present invention relates in particular to an improved therapeutic composition for endometri…
2009
2009
2009
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
other
2009
Amide compounds (I), are new. Amide compounds of formula (I), are new. q : 0 or 1 R 1>mono or bicyclic 6-12C aryl, 5-12 membered hetero aryl, 3-10C cycloalkyl, or 3-10 membered hetero cycloalkyl residue, which is unsubstituted or substitute…
2009
The present invention relates to non-steroidal progesterone receptor modulators of the general formula I, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise the…
2009
The present invention relates to non-steroidal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise the…
2009
The present invention relates to non-steroidal progesterone receptor modulators of the general formula I the use of the progesterone receptor modulators for producing medicaments, and pharmaceutical compositions which comprise these compoun…
2009
The present invention relates to nonsteroidal progesterone receptor modulators of the general formula (I), to the use of the progesterone receptor modulators for the preparation of pharmaceuticals, and to pharmaceutical compositions compris…
2009
The present invention relates to nonsteriodal progesterone receptor modulators of the general formula 1, the use of the progesterone receptor modulators for producing medicaments and also pharmaceutical compositions containing these compoun…
2008
This invention relates to nonsteroidal progesterone receptor modulators of general formula (I), a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutica…
2008
This invention relates to nonsteroidal progesterone receptor modulators of general formula (I), a process for their production, the use of progesterone receptor modulators for the production of pharmaceutical agents as well as pharmaceutica…
other
2008
The mineralcorticoid receptor antagonist comprises spironolactone, eplerenone and drospirenone. Glucocorticoid, progesterone receptor antagonist and estrogen receptor antagonist are also included. The estrogen is ethinylestradiol. - ACTIVIT…
2008
other
2008
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
2008
The aim of the present invention is the use of mineralcorticoid receptor antagonists for the production of a drug for the treatment of endometriosis. The present invention particularly relates to an improved therapeutic agent against endome…
other
2008
Amide compounds (I), are new. Amide compounds of formula (I), are new. A : H, Z substituted 1-8C-alkyl, 2-8C-alkenyl, 2-8C alkinyl, M substituted 3-10C-cycloalkyl, 3-12-membered heterocycloalkyl residue, where Z is cyano, halogen, hydroxy, …
other
2008
The invention relates to non-steroidal progesterone receptor modulators of general formula (I), use of the progesterone receptor modulators for the production of medicaments and pharmaceutical compositions containing said compounds. Said co…
other
2008
The present invention relates to non-steroidal progesterone receptor modulators of the general formula I, the use of the progesterone receptor modulators for the manufacture of medicaments, and pharmaceutical compositions which comprise the…